Table 1. Summary of reported cases of RCC metastasis to thyroid gland tumors, including the type of recipient tumor, interval from nephrectomy, other sites of metastases, and IHC profile of metastatic RCC.

IHC, immunohistochemistry; FA, follicular adenoma; FVPTC, follicular variant of papillary thyroid carcinoma; M, months; PTC, papillary thyroid carcinoma; RCC, renal cell carcinoma; TG, thyroglobulin; Y, years

#	Author	Recipient Tumor	Interval	Other Metastasis	IHC of Metastatic RCC
1	Rosai (cited by Ryška and Čáp [7])	FA	NA	NA	TG (-)
2	Baloch and LiVolsi [8]	FVPTC	2Y	Liver, pancreas	TG, CK19 (-)
3	Wolf et al. [9]	FA	2Y	NA	NA
4	Ryška and Čáp [7]	Hurthle cell (oncocytic) carcinoma	13M	Subcutaneous	AE1/AE3, vimentin, EMA (+); TG, CEA, CK19, calcitonin (-)
5	Qian et al. [10]	Hurthle cell Adenoma	synchronous	None	Vimentin, CD10 (+); TG, TTF-1 (-)
6	Koo et al. [3]	FA	5Y	None	CK, CD10, galectin-3 (equivocal); TG, TTF-1, calcitonin (-)
7	Bohn et al. [11]	PTC	2Y	Spinal vertebrae	RCC (+); TG (-)
8	Yu et al. [12]	FVPTC	3Y	None	CAM 5.2, CD10, vimentin (+); TG, TTF-1, RCC (-)
9	Medas et al. [2]	FA	6Y	None	CD10 (+); TG, TTF-1, galectin-3 (-)
10	Kefeli and Mete [4]	FVPTC	18Y	None	PAX-8, CD10 (+); vimentin (equivocal); TG, TTF-1, CEA, calcitonin (-)
11	Current case	FVPTC	14Y	Contralateral kidney	PAX-8, CAIX, galectin-3, vimentin (+); TG, TTF-1, CK7, CK19 (-)